Lipid Shell Microbubbles for Viral Transduction Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for viral transduction in CAR-T cell production are costly due to the high amount of viruses required, and existing technologies do not efficiently facilitate cell-to-cell viral transmission, which is more effective than free viral particle infection.
Innovation Solution
Flexible lipid shell microbubbles conjugated with ligands that bind viruses and target cells are used to enhance viral transduction by bringing viruses and cells into close proximity, reducing the need for high virus doses and leveraging the fluid nature of the lipid shell to increase interaction efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If free viral particles are used for transduction, then the process is simple, but the efficiency of viral transduction is low requiring high virus doses
Solution Approach 1:
The patent uses artificial virus-presenting cells (aVPCs) as intermediary structures that capture free viral particles and present them to target cells. The aVPCs consist of lipid shells displaying viral ligands that bind viral particles, creating a bridge between free viruses and target cells. This intermediary approach converts inefficient free viral particle transduction into efficient cell-to-cell-like transmission, dramatically reducing the virus dose required while increasing transduction efficiency.
Solution Approach 2:
The patent employs flexible lipid shell microbubbles as the structural basis for aVPCs. These flexible shells can dynamically interact with both viral particles and target cells, allowing the aVPCs to adapt their configuration during the transduction process. The fluid nature of the lipid shell enables efficient presentation of viral ligands and facilitates close proximity interactions with target cells, enhancing transduction efficiency while reducing viral particle requirements.
2Productivity
If cell-to-cell viral transmission is implemented, then transduction efficiency increases, but the system complexity increases
Solution Approach 1:
The aVPCs serve as simplified intermediary structures that capture viral particles and present them to target cells in a controlled manner. Rather than requiring complex cell-to-cell contact mechanisms, the aVPCs provide a straightforward platform where viral ligands are displayed on the lipid shell surface, enabling efficient transduction through a single-step binding process that reduces system complexity.
Solution Approach 2:
The patent uses disposable aVPCs that can be prepared in advance and used for transduction. These artificial virus-presenting cells are designed to be used once and then discarded, eliminating the need for complex reusable systems. The lipid shell microbubbles can be easily prepared and functionalized with viral ligands, providing a cost-effective and simple approach to achieving high-efficiency transduction without requiring complex infrastructure.
3Productivity
If high virus doses are used for transduction, then transduction efficiency is maintained, but manufacturing costs increase
Solution Approach 1:
The aVPCs act as viral particle amplifiers, where each aVPC can capture and present multiple viral particles to target cells. This intermediary approach allows a smaller total amount of viral material to achieve the same transduction efficiency that would otherwise require high virus doses. The lipid shell structure enables efficient viral ligand presentation, maximizing the utilization of each viral particle and reducing waste.
Solution Approach 2:
The patent changes the physical and chemical parameters of the transduction system by using lipid shell microbubbles with specific surface properties. The fluid lipid shell allows for optimal presentation of viral ligands, and the microbubble size and surface area can be tuned to maximize viral capture and presentation efficiency. These parameter optimizations enable high transduction efficiency with reduced viral material requirements, directly addressing the cost issue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly increases the efficiency of viral transduction, reduces the amount of virus needed, and streamlines CAR-T cell processing, making the process more cost-effective and efficient.
Implementation Method 1
Flexible lipid shell microbubbles conjugated with ligands that bind viruses and target cells are used to enhance viral transduction by bringing viruses and cells into close proximity
Implementation Method 2
leveraging the fluid nature of the lipid shell to increase interaction efficiency
Data Source
AI summary
A method for ex vivo transduction of biomolecules from viruses, viral vectors or virus-like particles into target cells and microbubbles for use in this method. A quantity of viruses, viral vectors or virus-like particles and target cells are bound to flexible lipid shell microbubbles, bringing these into close proximity to each other that allows viral transduction, transferring biomolecules from the viruses, viral vectors or virus-like particles into the target cells while the viruses, viral vectors or virus-like particles and the target cells are bound to the microbubbles.